Table 3.
Subgroup analysis of overall survival between the two groups with various factors
| Parameter | CRT plus Nimotuzumab (Arm A=15) | CRT (Arm B=14) | ||
|---|---|---|---|---|
| n (%) | Mean OS (95% CI) | n (%) | Mean OS (95% CI) | |
| Age | ||||
| ≤65 | 13 (86.7) | 37.6 (27.3-48.0) | 13 (92.9) | 28.9 (19.3-38.4) |
| >65 | 2 (13.3) | 12.0 (12.0-12.0) | 1 (7.1) | 33 (33-33) |
| Gender | ||||
| Male | 15 (100) | 35.8 (25.6-46.1) | 13 (92.9) | 30.1 (20.7-39.5) |
| Female | 0 (0) | -(-) | 1 (7.1) | 18 (18-18) |
| Histo-pathological type | ||||
| MDSCC | 8 (53.3) | 30.0 (19.3-40.7) | 8 (57.1) | 33.4 (19.3-47.5) |
| PDSCC | 4 (26.7) | 46.0 (22.2-69.7) | 1 (7.1) | 24 (24-24) |
| SCC | 1 (6.7) | 21.0 (21.0-21.0) | 2 (14.3) | 19 (0.0-46.4) |
| WDSCC | 2 (13.3) | 43.5 (20.6-66.3) | 3 (21.4) | 28 (18-37.8) |
| Chemotherapy type | ||||
| Cisplatin 40 mg | 11 (73.3) | 35.2 (21.9-48.4) | 10 (71.4) | 30.8 (19.5-42.2) |
| Cisplatin 50 mg | 2 (13.3) | 31.50 (22.6-40.3) | 3 (21.4) | 26 (6-45.8) |
| Carboplatin | 2 (13.3) | 43.5 (20.6-66.3) | 0 | - |
| Capecitabine | 0 | 0 | 1 (7.1) | 24 (24-24) |
SCC=Squamous cell carcinoma, PDSCC=Poorly differentiated SCC, WDSCC=Well differentiated SCC, MDSCC=Moderately differentiated SCC, CI=Confidence interval, CRT=Chemo-radiotherapy, OS=Overall survival